文献速递脑血管病外科神经重症

口服格列本脲预防急性缺血性卒中脑水肿

Oral Glyburide for the Prevention of Cerebral Edema in Acute Ischemic Stroke.
PubMed 文献 · World Neurosurg · 2024-04-07

本研究为单中心回顾性病历审查,纳入2018年1月1日至2022年3月31日期间接受至少1剂肠内格列本脲以预防脑水肿的44例急性缺血性卒中成人患者,评估格列本脲启动后需干预脑水肿的患者比例及低血糖发生情况;结果显示6例(14%)需干预脑水肿,7例(15%)发生低血糖,部分疗程组脑水肿干预率(10% vs 17%)和低血糖发生率(5% vs 23%)低于全疗程组。

要点

  • 44例患者中6例(14%)在格列本脲启动后需干预脑水肿。
  • 低血糖发生于7例(15%),全疗程组(5-7剂)为23%,部分疗程组(1-4剂)为5%。
  • 部分疗程组脑水肿干预率10%低于全疗程组17%,住院全因死亡率43%高于全疗程组31%。

核心结论

  • 尽管脑水肿干预率相对较低,但低血糖常见,尤其是在接受5-7剂肠内格列本脲以预防中重度急性缺血性卒中后脑水肿的患者中。

研究设计与样本

  • 单中心、回顾性病历审查,纳入2018年1月1日至2022年3月31日期间年龄≥18岁、诊断为急性缺血性卒中并接受至少1剂肠内格列本脲预防脑水肿的全部患者,最终纳入44例。

主要发现

  • 44例患者中6例(14%)在格列本脲启动后需干预脑水肿。
  • 基线美国国立卫生研究院卒中量表评分平均为19分。
  • 住院全因死亡率为36%(n=17),低血糖发生于7例(15%)。
  • 44例中20例(45%)接受部分疗程肠内格列本脲(1-4剂),24例(55%)接受全疗程(5-7剂)。
  • 部分疗程组较全疗程组:脑水肿干预率10% vs 17%(部分疗程组较低),低血糖发生率5% vs 23%(部分疗程组较低),住院全因死亡率43% vs 31%(部分疗程组较高)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The purpose of this study was to describe the impact of enteral glyburide on cerebral edema formation and hypoglycemia when used to treat patients diagnosed with acute ischemic stroke (AIS). METHODS: This study was a single-center, retrospective medical record review that included all patients aged ≥18 years diagnosed with AIS who received ≥1 dose of enteral glyburide for the prevention of cerebral edema from January 1, 2018 to March 31, 2022. The primary outcome was the percentage of patients requiring intervention for cerebral edema management after glyburide initiation, and the safety outcome was the occurrence of hypoglycemia in this patient population. RESULTS: The final evaluation included 44 patients, with 6 patients (14%) requiring intervention for cerebral edema after glyburide initiation. The average baseline National Institutes of Health stroke scale score was 19. Overall, in-hospital mortality was 36% (n = 17), and hypoglycemia occurred in 7 patients (15%). Of the 44 patients, 20 (45%) received a partial duration of enteral glyburide (1-4 doses) and 24 (55%) received a full duration of enteral glyburide (5-7 doses). The rate of intervention for cerebral edema (10% vs. 17%) and the incidence of hypoglycemia (5% vs. 23%) were lower in the partial duration than in the full duration group. The in-hospital all-cause mortality rate was higher in the partial duration group than in the full duration group (43% vs. 31%). CONCLUSIONS: Despite the relatively low rates of intervention for cerebral edema, hypoglycemia was common, especially for patients receiving 5-7 doses of enteral glyburide for the prevention of cerebral edema after moderate-to-severe AIS.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Wilkinson B, Delic J, Igneri L, et al. Oral Glyburide for the Prevention of Cerebral Edema in Acute Ischemic Stroke. World Neurosurg. 2024. PMID: 38593914. doi:10.1016/j.wneu.2024.04.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。